logo
China Is Building an AI Robot Uterus, and Are We Just Basically ‘Dune' Now?

China Is Building an AI Robot Uterus, and Are We Just Basically ‘Dune' Now?

Gizmodo8 hours ago
In a development that completely demolishes the line between robotics and reproductive science, China's Kaiwa Technology says it has introduced humanoid robots equipped with advanced artificial womb systems.
What could possibly go wrong with this line of experimentation?
Well, those of you who are Dune fans know exactly where this could theoretically go: a future filled with robots that take over humanity and have to be defeated and then outlawed in order to keep civilization going.
But we should back up a little before we jump right to that.
Let's first look a little closer at what Kaiwa says it has done thus far. It says it has a 'late stage' prototype that combines artificial intelligence with bioengineering and mimics the hormonal and physical processes of pregnancy. The robots have biosynthetic organs that the company claims are capable of simulating gestation in a controlled environment, including feeding an embryo or fetus via liquid nutrients. Kaiwa claims its womb-endowed robots will eventually retail for about $14,000, as SlashGear reports.
How to Build an Artificial Womb
Kaiwa has not disclosed whether it's running tests on biological material or with human eggs, sperm, or embryos. It also does not explain how an actual baby would be born.
Well, the first and most obvious thing is that a robotic uterus could easily damage or terminate a fetus if it does not work correctly. Babies are not hydroponic, after all, and depend on a complex mixture of nutrients and signals from the highly complicated placenta, which is really the workhorse of pregnancy (aside from the pregnant person carrying the fetus).
Creating an AI placenta would be much more of a Holy Grail in science than a robotic womb, because it grows, changes, and expands as the fetus develops and is far more delicate and difficult to replicate.
Kaiwa did not respond to a request for comment. It has not said whether it is also developing a humanoid placenta or if that is already part of the robot uterus.
'This is a revolutionary step,' Kaiwa said in a statement. 'Our robots could help scientists explore the intricacies of gestation and, someday, provide alternatives to biological reproduction.'
More worrying, there have been very few reports of any ethical vetting of what Kaiwa is using to test this new technology or how advanced it is. There is serious ethical debate over the future of human reproduction and how a robotic component would affect the relationships and ownership of embryos or children conceived or delivered that way, particularly in countries like the U.S., in which some states recognize embryos as property.
The pros? If true and ethically vetted, this new technology could potentially open new avenues for infertility research and reproductive assistance. It could provide surrogacy at a much reduced cost of around $14,000 (the cost of the robot) for people who can't have a child, compared to a human surrogacy fee of about $100,000 to $200,000 in the U.S.
The cons? The patchwork of laws applying to reproductive tech is a changing pattern depending on the country, the region, the governing bodies (like the European Union), cultural roles, religious rules, and the rights of parenthood and surrogates.
Who would own each part of the process of creating a human fetus in a robot would have to be exhaustively studied and debated, and it would very likely fall short of most definitions of bioethical standards. Who then oversees that process and enforces its rules should there be infractions is a whole other ball of legal and ethical wax.
The prospect of these robots being artificially intelligent raises another important issue. Super-sophisticated robots may eventually be granted personhood status, meaning they'd be protected under the same laws as human beings. And should these robots eventually feel and experience emotions in a manner similar to humans, that would introduce yet another layer of ethical and legal complexity.
An artificial womb could also help human babies survive extreme prematurity and prevent serious complications like brain injuries, lung damage, or blindness. Indeed, advances in neonatal care may drive this technology forward, regardless of any overt attempt to create a robotic uterus.
Conversely, critics worry about the potential misuse or dehumanization of the gestation process, noting that artificial wombs could lead to creating 'human-like entities' without full biological rights or moral considerations.
'Pregnancy is an extremely complex process, with each step being extremely delicate and critical,' Yi Fuxian, an obstetrician at the University of Wisconsin–Madison, told Newsweek.
He said the robot is 'likely just a gimmick' and that synthetic gestation has caused problems in sheep, and that 'many health risks emerge at different ages, not to mention mental health issues.'
Recent reporting has found that China and South Korea's tech sectors are watching the pregnancy robot saga closely.
South Korea already has robots as 10% of its workforce. In January 2024, its Ministry of Trade, Industry, and Energy unveiled the Fourth Intelligent Robot Basic Plan, which will plow $2.24 billion in public and private investments by 2030 to advance automation across most business sectors.
Countries with declining birth rates like Japan and South Korea may also be major marketplaces for a synthetic uterus.
South Korea has declared its lack of babies a national emergency and has been attempting to lure people into becoming parents with a new ministry focused on providing housing, immigration, and other demographic markers that may be keeping people from having any or more children.
The county has already invested more than $200 billion in fertility programs over the last 18 years, but thus far the birth rate has stayed low. Maybe having a government-subsidized pregnancy robot could change that.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Adani Takes on Airport Aggregators With Loyalty, Lounge Sales
Adani Takes on Airport Aggregators With Loyalty, Lounge Sales

Skift

time21 minutes ago

  • Skift

Adani Takes on Airport Aggregators With Loyalty, Lounge Sales

Adani Digital Labs (ADL) has rolled out a set of digital initiatives to improve the passenger experience across its airports. The package includes a redesigned Adani OneApp, a new loyalty program called Adani Rewards, and a digital lounge-booking service. Through these features, passengers can book lounges, browse duty-free catalogues, get deliveries at the gate, place multi-cart orders, reserve parking, track flight status in real time, and access high-speed Wi-Fi. Adani Rewards, which the company says is India's first airport-specific loyalty program, will cover food and beverage, retail, duty-free, parking, and meet-and-greet services. The program will operate independently of airline choice or ticket class. ADL has also opened a 150-seat tech hub in Ahmedabad to drive localized travel innovation. Adani's Competition With Aggregators: Adani's move positions the group against airport service aggregators. Adani operates seven airports

Rivaroxaban or Combo Therapy: A Winner for All Ages?
Rivaroxaban or Combo Therapy: A Winner for All Ages?

Medscape

time21 minutes ago

  • Medscape

Rivaroxaban or Combo Therapy: A Winner for All Ages?

TOPLINE: In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy reduced the risks for major cardiovascular events (MACE) and major bleeding across all adult age groups. METHODOLOGY: Researchers performed a post hoc analysis of data from the AFIRE trial, conducted in Japan, to assess the age-stratified effects of rivaroxaban monotherapy vs treatment with rivaroxaban plus an antiplatelet agent. The analysis included 2215 patients (mean age, 74.3 years; 79.1% men) with AF and stable CAD more than 1 year after revascularization or angiographically confirmed CAD that did not need revascularization. Patients were randomly assigned to 10 mg or 15 mg of rivaroxaban monotherapy, depending on creatinine clearance, or combination therapy involving rivaroxaban plus aspirin or a P2Y12 inhibitor (at the physician's discretion). The patients were stratified into four age groups: younger than 70 years, 70-74 years, 75-79 years, and 80 years or older. The primary efficacy endpoint was MACE, defined as a composite of stroke, myocardial infarction, systemic embolism, unstable angina requiring revascularization, or death; the primary safety endpoint was major bleeding. The patients were followed for up to 45 months. TAKEAWAY: Across the age spectrum, rivaroxaban alone matched combination therapy for reducing the risks for MACE and major bleeding. However, rivaroxaban monotherapy, compared with combination therapy, was associated with a more pronounced reduction in the risk for MACE among patients aged 80 years or older (hazard ratio [HR], 0.61; 95% CI, 0.40-0.93) and a more pronounced reduction in the risk for major bleeding among those younger than 70 years (HR, 0.23; 95% CI, 0.06-0.79). IN PRACTICE: 'Although the present study did not clarify the factors involved, it is important to reaffirm that rivaroxaban monotherapy effectively reduces net adverse clinical events, which comprehensively include both thrombotic and hemorrhagic events, across a wide age range, even in older patients,' the researchers reported. SOURCE: This study was led by Junichi Yamaguchi, MD, PhD, of the Department of Cardiology at Tokyo Women's Medical University in Tokyo, Japan. It was published online on August 13, 2025, in JAMA Cardiology. LIMITATIONS: The open-label design of the trial may have introduced bias. As a post hoc analysis, this study was underpowered, and differences between the two arms may have been missed due to small sample size. The antiplatelet agent was chosen by the treating physician and was not standardized. DISCLOSURES: This study received support from the Japan Cardiovascular Research Foundation through a contract with Bayer Yakuhin, Ltd. Several authors reported receiving grants, personal fees, and endowments from multiple sources, including Bayer, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Abbott, among others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

OpenAI-Challenger Manus Projects Annual Revenue of $90 Million
OpenAI-Challenger Manus Projects Annual Revenue of $90 Million

Bloomberg

time22 minutes ago

  • Bloomberg

OpenAI-Challenger Manus Projects Annual Revenue of $90 Million

The Chinese-founded company behind AI pioneer Manus said it's forecast an annual revenue run rate of $90 million, offering a first glimpse at the value of its business. The figure was given by Manus's co-founder Peak Ji on Wednesday at an event in Singapore. A spokesperson for Butterfly Effect, the startup that backs Manus's autonomous AI agents as well as a previous product known as Monica, said the amount comprises all sales under its banner and Manus contributes by far the most.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store